Closely-watched start-up Caribou Biosciences announced 02 April that it has brought in $11m in Series A round financing through a group of deep-pocketed investors, including European pharma giant Novartis.
The biotech is a developer of CRISPR-cas9 technology, a type of gene editing that has the oncology world abuzz.